121,700.00
-700(-0.57%)
Currency In KRW
Address
221, Pangyoyeok-ro
Seongnam-si, 13494
Korea, Republic of
Phone
82 31 8093 0114
Website
Sector
Healthcare
Industry
Biotechnology
Employees
241
First IPO Date
July 02, 2020
| Name | Title | Pay | Year Born |
| Dong Hoon Lee | Chief Executive Officer, President & Executive Director | 1.28B | 1968 |
| Jiyoung Jung | Chief Financial Officer & Executive Director | 0 | 1973 |
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, discovery, and development of drugs for the treatment of central nervous system disorders. The company is developing Cenobamate for the treatment of epilepsy; Solriamfetol for the treatment of excessive daytime sleepiness in narcolepsy or obstructive sleep apneal; Carisbamate that is in Phase 1b/2 trials to treat lennox-gastaut syndrome; and Relenopride, which is in Phase 2 clinical trials to treat rare neurological disease. It is also developing SKL13865 that is in Phase 1 clinical trials to treat attention deficit/hyperactivity disorder; SKL20540, which is in Phase 1 clinical trials for the treatment of schizophrenia; SKL-PSY that is in Phase 1 clinical trials to treat bipolar disorder; and SKL24741, which is in Phase 1 clinical trials for the treatment of epilepsy. The company was founded in 2011 and is headquartered in Seongnam, South Korea. SK Biopharmaceuticals Co., Ltd. operates as subsidiary of SK Inc.